Drug Trial Radar · NCT07603713
Efficacy and Safety of LP-005 Injection in Patients With Moderate-to-Severe Periodontitis
Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
May 1, 2026
Primary completion
Nov 12, 2026
Study completion Mar 23, 2027
Sponsor
- Lead sponsor
- Longbio Pharma (Suzhou) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study designed to evaluate the clinical efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of multiple local injections of different doses of LP-005 injection in patients with moderate-to-severe periodontitis, and to investigate changes in biomarker levels.
Conditions
- Periodontitis
Interventions
LP-005 InjectionDrug
LP-005 is a bifunctional antibody fusion protein consisting of an anti-human C5 monoclonal antibody and a human complement regulatory protein, formulated as a sterile injectable solution. Each vial contains 300 mg of LP-005 in 6 mL (50 mg/mL). The LP-005 is administered via interdental papilla injection.
Placebo InjectionDrug
Placebo is a sterile injectable solution matched to LP-005 for appearance, formulation, and administration, with 0 mg of active ingredient per 6 mL vial.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Gingival Index (GI)Time frame: Day 43, Day 85, Day 127, and Day 169
- Change from Baseline in Bleeding Index (BI)Time frame: Day 43, Day 85, Day 127, and Day 169
- Change from Baseline in Probing Pocket Depth (PD)Time frame: Day 43, Day 85, Day 127, and Day 169
- Change from Baseline in Clinical Attachment Loss (AL)Time frame: Day 43, Day 85, and Day 127, Day 169
- Change from Baseline in Plaque Index (PI)Time frame: Day 43, Day 85, Day 127, and Day 169
- Change from Baseline in Alveolar Bone Defect HeightTime frame: Day 85, and Day 169
- Incidence of Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to approximately 24 weeks
- Detect Pharmacokinetic (PK) Characteristics of LP-005Time frame: Up to approximately 24 weeks
- Gingival Crevicular Fluid (GCF) Concentration of LP-005Time frame: Up to approximately 24 weeks
- Detect Pharmacodynamics (PD) Characteristics of LP-005Time frame: Up to approximately 24 weeks
- Anti-Drug Antibody (ADA) and Neutralizing Antibody (NAb) AssessmentTime frame: Up to approximately 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University School and Hospital of Stomatology
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.